LLY

988.33

+0.72%↑

JNJ

240.32

+0.33%↑

ABBV

229.95

-0.9%↓

NVS

159.76

-0.49%↓

AZN

194.37

-1.51%↓

LLY

988.33

+0.72%↑

JNJ

240.32

+0.33%↑

ABBV

229.95

-0.9%↓

NVS

159.76

-0.49%↓

AZN

194.37

-1.51%↓

LLY

988.33

+0.72%↑

JNJ

240.32

+0.33%↑

ABBV

229.95

-0.9%↓

NVS

159.76

-0.49%↓

AZN

194.37

-1.51%↓

LLY

988.33

+0.72%↑

JNJ

240.32

+0.33%↑

ABBV

229.95

-0.9%↓

NVS

159.76

-0.49%↓

AZN

194.37

-1.51%↓

LLY

988.33

+0.72%↑

JNJ

240.32

+0.33%↑

ABBV

229.95

-0.9%↓

NVS

159.76

-0.49%↓

AZN

194.37

-1.51%↓

Home・Aandelen Lijst・Altimmune Inc

Altimmune Inc

Gesloten

3.54 0.85

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

3.39

Max

3.74

Belangrijke statistieken
By Trading Economics
Inkomsten	3.1M -19M
Verkoop	5K
Winstmarge	-380,280
Werknemers	59
EBITDA	4.4M -18M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+220% upside

Dividenden
By Dow Jones
Volgende Winsten	12 mei 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	171M 521M
Vorige openingsprijs	2.69
Vorige sluitingsprijs	3.54

Technische score

By Trading Central

Vertrouwen

Bullish Evidence

5.365 / 6.0486 Steun & Weerstand

Altimmune Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

6 mrt 2026, 19:32 UTC

Acquisities, Fusies, Overnames

Diana Shipping Increases Offer to Acquire Genco -- Update

6 mrt 2026, 17:44 UTC

Acquisities, Fusies, Overnames

Lonza to Offload Majority Stake in Capsule Business to Lone Star in $2.2 Billion Deal

6 mrt 2026, 22:26 UTC

Belangrijke Nieuwsgebeurtenissen

Why $100 Oil Is Now in Sight. Who Wins, Who Loses. -- Barrons.com

6 mrt 2026, 22:07 UTC

Marktinformatie

Acquisities, Fusies, Overnames

Boeing Says Spirit Acquisition Will Help Improve Safety -- Market Talk

6 mrt 2026, 22:03 UTC

Marktinformatie

Global Equities Roundup: Market Talk

6 mrt 2026, 22:03 UTC

Marktinformatie

Boeing CEO's Pay Nears $24 Million During Recovery Phase -- Market Talk

6 mrt 2026, 21:50 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Financial Services Roundup: Market Talk

6 mrt 2026, 21:37 UTC

Winsten

Salesforce Stock Might Not Be an AI Loser After All -- Barrons.com

6 mrt 2026, 21:25 UTC

Belangrijke Nieuwsgebeurtenissen

How The Iran War Impacts Ukraine. -- Barrons.com

6 mrt 2026, 21:17 UTC

Winsten

Burlington Stores' Strong Year Should Lift the Stock. What Comes Next. -- Barrons.com

6 mrt 2026, 20:50 UTC

Winsten

Marvell Stock Pops 20%. Semiconductor Earnings Show AI Demand Is Strong. -- Barrons.com

6 mrt 2026, 20:46 UTC

Winsten

Nike Reports $300 Million Pretax Charge Related to Job Cuts -- Barrons.com

6 mrt 2026, 20:31 UTC

Belangrijke Nieuwsgebeurtenissen

Oil Prices Soar Past $90. Trump Demands 'Unconditional Surrender' From Iran -- and Kuwait Cut Production. -- Barrons.com

6 mrt 2026, 20:18 UTC

Marktinformatie

Oil Makes Record Weekly Gains As Strait of Hormuz Stays Shut -- Market Talk

6 mrt 2026, 20:12 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

U.S. Natural Gas Futures Gain on Global Energy Turmoil -- Market Talk

6 mrt 2026, 19:10 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

$150 Oil Seen As Realistic If Hormuz Closure Lasts -- Market Talk

6 mrt 2026, 18:54 UTC

Marktinformatie

Fed's Hammack: Dollar Hasn't Lost Prime Status -- Market Talk

6 mrt 2026, 18:44 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

U.S. Oil Rig Count Increases By 4 to 411 -- Market Talk

6 mrt 2026, 18:08 UTC

Winsten

Samsara Stock Jumps 16% After Earnings. Why the CEO Isn't Worried About AI. -- Barrons.com

6 mrt 2026, 18:04 UTC

Winsten

Marvell Stock Surges on Earnings. It's Not Just a Custom AI Chip Story. -- Barrons.com

6 mrt 2026, 18:04 UTC

Winsten

Samsara Stock Jumps 16% After Earnings. Why the CEO Isn't Worried About AI. -- Barrons.com

6 mrt 2026, 17:49 UTC

Marktinformatie

AI-Driven Picks-And-Shovels Bet Comes With Risks -- Market Talk

6 mrt 2026, 17:46 UTC

Belangrijke Nieuwsgebeurtenissen

Kuwait Cuts Oil Production as Fallout From Iran Conflict Intensifies -- Update

6 mrt 2026, 17:40 UTC

Marktinformatie

Winsten

Marvell's Long-Term Outlook Well-Received By Investors -- Market Talk

6 mrt 2026, 17:40 UTC

Winsten

Marvell Stock Surges on Earnings. It's Not Just a Custom AI Chip Story. -- Barrons.com

6 mrt 2026, 17:32 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

No Quick Solution for Hormuz Shipping as U.S. Oil Tops $90 -- Market Talk

6 mrt 2026, 17:28 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Aluminum Rising as Strait of Hormuz Stays Locked -- Market Talk

6 mrt 2026, 17:20 UTC

Marktinformatie

Winsten

Auto & Transport Roundup: Market Talk

6 mrt 2026, 17:20 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Basic Materials Roundup: Market Talk

6 mrt 2026, 17:20 UTC

Acquisities, Fusies, Overnames

BlackRock Sticks to Redemption Minimum on Credit Fund, Sends Shares Lower -- WSJ

Peer Vergelijking

Prijswijziging

Altimmune Inc Prognose

Koersdoel

By TipRanks

220% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 11.2 USD 220%

Hoogste 20 USD

Laagste 4.01 USD

Gebaseerd op 6 Wall Street-analisten die 12-maands prijsdoelen bieden voor Altimmune Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

6 ratings

Buy

Hold

Sell

Gebaseerd op 6 analisten die aandelenratings hebben gegeven aan Altimmune Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

5.365 / 6.0486Steun & Weerstand

Recent bullish events outweigh bearish events.

All events are bearish.

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Altimmune Inc

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.